 Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
- Reductase Inhibitors, HMG-CoA
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Statins
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2001 | 2 | 1 | 3 | | 2002 | 4 | 2 | 6 | | 2003 | 7 | 1 | 8 | | 2004 | 4 | 1 | 5 | | 2005 | 11 | 0 | 11 | | 2006 | 10 | 5 | 15 | | 2007 | 13 | 5 | 18 | | 2008 | 8 | 7 | 15 | | 2009 | 9 | 5 | 14 | | 2010 | 7 | 5 | 12 | | 2011 | 6 | 6 | 12 | | 2012 | 5 | 2 | 7 | | 2013 | 8 | 0 | 8 | | 2014 | 10 | 2 | 12 | | 2015 | 17 | 5 | 22 | | 2016 | 12 | 3 | 15 | | 2017 | 11 | 8 | 19 | | 2018 | 14 | 6 | 20 | | 2019 | 10 | 9 | 19 | | 2020 | 15 | 3 | 18 | | 2021 | 10 | 2 | 12 | | 2022 | 18 | 0 | 18 | | 2023 | 10 | 2 | 12 | | 2024 | 7 | 5 | 12 | | 2025 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Bittner V, Linnebur SA, Dixon DL, Forman DE, Green AR, Jacobson TA, Orkaby AR, Saseen JJ, Virani SS. Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society. J Clin Lipidol. 2025 Mar-Apr; 19(2):215-237.
-
Erlandson KM, Umbleja T, Ribaudo HJ, Schrack JA, Overton ET, Fichtenbaum CJ, Fitch KV, Roa JC, Diggs MR, Wood K, Zanni MV, Bloomfield GS, Malvestutto C, Aberg JA, Rodriguez-Barradas MC, Morones RG, Breaux K, Douglas PS, Grinspoon SK, Brown TT. Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clin Infect Dis. 2025 02 24; 80(2):425-433.
-
Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, Dunbar RL, Ketchum SB, Tardif JC, Martens FMAC, Ballantyne CM, Szarek M, Mason RP. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
-
Kao DP, Martin JL, Aquilante CL, Shalowitz EL, Leyba K, Kudron E, Reusch JEB, Regensteiner JG. Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration. BMJ Open Diabetes Res Care. 2024 Dec 05; 12(6).
-
Hirpara A, Ackert-Bicknell CL, Patel VV. Impact of Low-density Lipoprotein Levels on Rates of Pseudarthrosis After Anterior Cervical Discectomy and Fusion. Spine (Phila Pa 1976). 2025 Mar 01; 50(5):294-303.
-
Bhatia HS, Wandel S, Willeit P, Lesogor A, Bailey K, Ridker PM, Nestel P, Simes J, Tonkin A, Schwartz GG, Colhoun H, Wanner C, Tsimikas S. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. 2025 Jan 28; 151(4):312-321.
-
Shah NP, Mulder H, Lydon E, Chiswell K, Hu X, Lampron Z, Cohen L, Patel MR, Taubes S, Song W, Mulukutla SR, Saeed A, Morin DP, Bradley SM, Hernandez AF, Pagidipati NJ. Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems. J Am Heart Assoc. 2024 Nov 05; 13(21):e035610.
-
Shah NP, Mulder H, Lydon E, Chiswell K, Hu X, Lampron Z, Cohen L, Patel MR, Taubes S, Song W, Mulukutla SR, Saeed A, Morin DP, Bradley SM, Hernandez AF, Pagidipati NJ. Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease. Am Heart J. 2025 Jan; 279:50-58.
-
Hess CN, Daffron A, Nehler MR, Morrison JT, Buchanan CE, Szarek M, Anderson VE, Cannon CP, Hsia J, Saseen JJ, Bonaca MP. Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2024 Jun 25; 83(25):2658-2670.
-
Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Mason RP, Ketchum SB, Lira Pineda A, Doyle RT, Steg PG. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024 Apr 23; 83(16):1529-1539.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|